The idea that retinol thins your skin likely comes from some of the short-term side effects it causes when you first start ...

Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, reported preclinical data this week at the Association for Research in ...

Cognition Therapeutics has announced positive topline outcomes from the Phase II MAGNIFY trial of zervimesine in adult ...

Palatin Technologies, Inc. (OTC PINK: PTNT), a biopharmaceutical company advancing innovative treatments targeting the melanocortin receptor system, today announced new preclinical data on its ...

Huge numbers of Brits could be driving without having notified the DVLA about their pre-existing conditions that should be ...

Pham, who’s accused of violating the Federal Food, Drug, and Cosmetic Act, has pleaded guilty to a federal charge: receipt in ...

Beacon Therapeutics announces phase 2 interim 6 months data from DAWN trial of Laru-zova: London Friday, May 9, 2025, 18:00 Hrs [IST] Beacon Therapeutics Holdings Limited, a leadi ...

Findings highlight PL9654 and PL9655's potential to treat diabetic retinopathy through inflammation resolution, vascular stabilization, and neuroprotection PL9654 ...

High blood sugars have long been known to cause eye damage in diabetics. However, new research has found that low blood sugar ...

The consensus rating for Ocugen is Buy, derived from 4 analyst ratings. An average one-year price target of $7.25 implies a ...

Aiming to enhance the eye care treatment, Sealdah Division of Eastern Railway has introduced Advanced OCT-A Technology at BR Singh Hospital.

In addition to the presentations, Viral Kansara, PhD, Vice President, Preclinical Development moderated an ARVO session entitled “Retina/RPE: New drugs, mechanisms of action, and toxicity” and Dr.